文献速递膀胱癌与上尿路尿路上皮癌

尿液分子病理用于新诊断膀胱尿路上皮癌的基因分型与监测

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
PubMed 文献 · J Urol · 2021-06-01

结果显示尿液肿瘤DNA与组织DNA在突变负荷和变异频率等指标上高度一致,以组织DNA为参考的尿液检测特异性99.3%、敏感性86.7%、阳性预测值67.2%、阴性预测值99.8%、诊断准确率99.1%。术前尿液或组织DNA丰度越高,无复发生存越差。

要点

  • 尿液肿瘤DNA与组织DNA的突变谱高度一致,可作为膀胱癌基因分型的可靠替代。
  • 尿液肿瘤DNA检测敏感性86.7%、特异性99.3%,阴性预测值达99.8%。
  • 术前尿液或组织DNA丰度越高与更差的无复发生存相关。

核心结论

  • 尿液分子病理能提供膀胱癌完整基因谱,是新诊断膀胱尿路上皮癌基因分型和监测的可靠替代。

主要发现

  • 肿瘤DNA与尿液肿瘤DNA在癌症细胞分数、变异等位基因频率和肿瘤突变负荷等指标上一致,但与循环肿瘤DNA不一致。
  • 循环肿瘤DNA中相当比例的变异来源于克隆性造血,而肿瘤DNA与尿液肿瘤DNA的突变景观高度相似。
  • 以肿瘤DNA为参考,尿液肿瘤DNA检测特异性99.3%、敏感性86.7%、阳性预测值67.2%、阴性预测值99.8%、诊断准确率99.1%。
  • 术前尿液肿瘤DNA或肿瘤DNA丰度越高与更差的无复发生存相关。
  • 尿液肿瘤DNA中可检出FGFR3变异和ERBB2扩增等可操作变异。

临床怎么用

  • 可考虑用尿液肿瘤DNA检测替代组织活检进行膀胱癌基因分型和术后监测。
  • 尿液肿瘤DNA中可检出FGFR3变异和ERBB2扩增等可操作变异,为靶向治疗提供依据。
  • 术前尿液肿瘤DNA丰度或可辅助评估无复发生存风险。

局限性

  • 循环肿瘤DNA中克隆性造血干扰较大,不宜作为膀胱癌基因分型替代。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Next-generation sequencing (NGS)-based profiling of both urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) shows promise for noninvasive detection and surveillance of urothelial bladder cancer (UBC). However, the analytical performance of these assays remains undefined in the real-world setting. Here, we sought to evaluate the concordance between tumor DNA (tDNA) profiling and utDNA or ctDNA assays using a UBC patient cohort from the intended-use population. MATERIALS AND METHODS: Fifty-nine cases with pathologically confirmed disease and matching tissue/urine pairs were prospectively enrolled. Baseline peripheral blood mononuclear cell and plasma specimens were collected during clinic visits. The PredicineCARETM NGS assay was applied for ultra-deep targeted sequencing and somatic alteration identification in tDNA, utDNA and ctDNA. RESULTS: Diverse quantitative metrics including cancer cell fraction, variant allele frequency and tumor mutation burden were invariably concordant between tDNA and utDNA, but not ctDNA. The mutational landscapes captured by tDNA or utDNA were highly similar, whereas a considerable proportion of ctDNA aberrations stemmed from clonal hematopoiesis. Using tDNA-informed somatic events as reference, utDNA assays achieved a specificity of 99.3%, a sensitivity of 86.7%, a positive predictive value of 67.2%, a negative predictive value of 99.8% and a diagnostic accuracy of 99.1%. Higher preoperative utDNA or tDNA abundance correlated with worse relapse-free survival. Actionable variants including FGFR3 alteration and ERBB2 amplification were identified in utDNA. CONCLUSIONS: Urine-based molecular pathology provides a valid and complete genetic profile of bladder cancer, and represents a faithful surrogate for genotyping and monitoring newly diagnosed UBC.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Zhang R, Zang J, Xie F, et al. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer. J Urol. 2021. PMID: 34061567. doi:10.1097/JU.0000000000001878

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。